[go: up one dir, main page]

CN109363764A - RF impedance prevents carcinoma of endometrium caused by Mammary cancer endocrinotherapy - Google Patents

RF impedance prevents carcinoma of endometrium caused by Mammary cancer endocrinotherapy Download PDF

Info

Publication number
CN109363764A
CN109363764A CN201811115148.4A CN201811115148A CN109363764A CN 109363764 A CN109363764 A CN 109363764A CN 201811115148 A CN201811115148 A CN 201811115148A CN 109363764 A CN109363764 A CN 109363764A
Authority
CN
China
Prior art keywords
endometrium
impedance
carcinoma
energy
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201811115148.4A
Other languages
Chinese (zh)
Inventor
吴晓杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiaxing Maternity and Child Health Care Hospital
Original Assignee
Jiaxing Maternity and Child Health Care Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiaxing Maternity and Child Health Care Hospital filed Critical Jiaxing Maternity and Child Health Care Hospital
Priority to CN201811115148.4A priority Critical patent/CN109363764A/en
Publication of CN109363764A publication Critical patent/CN109363764A/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B18/12Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00559Female reproductive organs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00571Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for achieving a particular surgical effect
    • A61B2018/00595Cauterization
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00636Sensing and controlling the application of energy
    • A61B2018/00696Controlled or regulated parameters
    • A61B2018/00702Power or energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00636Sensing and controlling the application of energy
    • A61B2018/00773Sensed parameters
    • A61B2018/00875Resistance or impedance

Landscapes

  • Health & Medical Sciences (AREA)
  • Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plasma & Fusion (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses RF impedance prevent Mammary cancer endocrinotherapy caused by carcinoma of endometrium, using RF energy by endometrium gasify successive elimination inner membrance;Impedance measurement: the impedance value between measuring electrode and tissue, when impedance is increased to 50 Ω, transmitting signal to RF energy transmitter, RF energy transmitter stops issuing RF energy, completes to eliminate.RF impedance control technology carries out the risk that the postoperative prolonged application endocrine therapy of Thermal balloon endometrial ablation energy effectively preventing breast carcinoma patient causes carcinoma of endometrium;And at home and abroad the expression study of first passage tumor suppressor gene VHL, synapse nucleoprotein, vascular endothelial growth factor and its receptor verifies conclusions.Before patient with breast cancer carries out long-term endocrine therapy after surgery, the prevention scheme that RF impedance control technology carries out endometrium removal is carried out, can effectively prevent the postoperative risk for carrying out carcinoma of endometrium caused by long-term endocrine therapy of patient with breast cancer.

Description

RF impedance prevents carcinoma of endometrium caused by Mammary cancer endocrinotherapy
Technical field
The present invention relates to carcinomas of endometrium, and in particular to RF impedance prevents son caused by Mammary cancer endocrinotherapy Endometrial carcinoma.
Background technique
Previously, when carrying out endocrinotherapy for patient with breast cancer, endometrium is obviously thickened or diagnostic is scraped Palace prompts Endometrial Diseases patient, often takes the preventative excision in uterus, but data shows the uterectomy of 30%-40% Intraoperative compliaction or postoperative untoward reaction can occur for women, and spirituality sex dysfunction can occur for 30% uterectomy women And some other mental disease, needless to say the internal sex hormone due to caused by the loss in the uterus as sex hormone target organ Level variation, therefore, the preventative excision in uterus is more difficult to be accepted by patients.
And B ultrasound monitoring and regular diagnostic curettage are constantly carried out in duration of medication, uterus may occur at any time Lesion brings huge financial burden and psychological pressure to patient again.
It is international popular problem that carcinoma of endometrium how is avoided when using endocrinotherapy. Currently, it is directed to the postoperative endocrine therapy of Estrogen and progesterone receptors breast cancer patients with positive, to reduce carcinoma of endometrium chance of occurrence, Some patientss can select the preventative excision in uterus to carry out uterus pretreatment to avoid the generation of carcinoma of endometrium, but due to operation Psychological problems caused by internal sex hormone change, uterectomy caused by risk, uterectomy, actually clinical rarer trouble Person can receive the preventative excision in uterus.Most of Postoperative Patient with Breast Cancer for receiving endocrine therapy is regular progress uterus at present Diagnostic curettage, discovery lesion are performed the operation again, but a kind of often passive treatment, can not be prevented in advance.Therefore, seek one kind Safely and effectively means make in the prevention for not influencing to carry out carcinoma of endometrium under the premise of internal sex hormone change, Reservations uterus The endocrine therapy of Mammary cancer can carry out, safely and effectively for a long time, avoid the generation of carcinoma of endometrium, very necessary.
Summary of the invention
In view of the above technical problems, the present invention provides RF impedances to prevent son caused by Mammary cancer endocrinotherapy Endometrial carcinoma is at home and abroad put forward for the first time, and RF impedance control technology carries out Thermal balloon endometrial ablation energy effectively preventing breast carcinoma The postoperative prolonged application endocrine therapy of patient causes the risk of carcinoma of endometrium;And at home and abroad first passage tumor suppressor gene VHL, The expression study of synapse nucleoprotein, vascular endothelial growth factor and its receptor verifies conclusions.
Before patient with breast cancer carries out long-term endocrine therapy after surgery, carries out RF impedance control technology and carry out endometrium The prevention scheme of removal can effectively prevent carcinoma of endometrium caused by the postoperative long-term endocrine therapy of progress of patient with breast cancer Risk.
In order to solve the above technical problems, one technical scheme adopted by the invention is that: RF impedance prevents Mammary cancer Carcinoma of endometrium caused by endocrinotherapy, using RF energy by endometrium gasify successive elimination inner membrance;
Impedance measurement: the impedance value between measuring electrode and tissue, when impedance is increased to 50 Ω, transmitting signal to RF energy emits Device, RF energy transmitter stop issuing RF energy, complete to eliminate.
The beneficial effects of the present invention are:
Lower endometrium removal is controlled by RF impedance, prevents the postoperative prolonged application endocrine therapy of patient with breast cancer and causes The generation of carcinoma of endometrium, this technology are different from the scheme for preventing carcinoma of endometrium with preventative uterectomy in the past, make Patient is not influencing hormone in vivo level variation, under the premise of Reservations uterus, the endocrine therapy of safe carries out breast cancer, The clinical application of technology, will make numerous patient with breast cancers, and especially young patient improves life while improving survival rates Deposit quality.
Control lower endometrium removal by RF impedance, prevent the postoperative prolonged application endocrine therapy of patient with breast cancer and Cause the generation of carcinoma of endometrium, this technology, which is different from, passively to be monitored endometrium thickness by regular B ultrasound in the past and determine Phase carries out endometrium diagnostic curettage, waits endometrium that the scheme that lesion (or even canceration) performs the operation again, this skill occurs The utilization of art enables the patient to the long-term endocrine therapy of safe progress, reduces the financial burden and psychological pressure of patient, Significantly improve the life quality of patient.
Specific embodiment
With reference to embodiment, the specific embodiment of the present invention is further described.
The endometrial resection system that RF impedance control technology is formed utilizes RF energy using impedance control as principle The inner membrance of endometrium or simulation womb is gasified, electric current flows through tissue, and the impedance value between electrode and tissue is with treatment time Increase, the elimination of inner membrance are continuously increased, and as tissue impedance is continuously increased, when impedance is increased to 50 Ω, that is, cutting off depth is more than When shallow muscle layer, equipment, that is, RF energy transmitter is automatically stopped operation, indicates that endometrium has been gasified totally, has eliminated;In addition, Persistently removal cuts off the liquid at position and the tissue of vaporization to distinctive moisture transmission technology during excision.
Compared with other similar techniques, RF impedance endometrial resection technology has following advantage:
(1) without cumbersome preoperative pretreatment or using expensive pretreatment drug, can the menstrual cycle each period into Row;
(2) operating time is short, and Mean treatment duration 90 seconds;
(3) personalized treatment: automatic to monitor Endometrectomy depth using impedance control as principle;
(4) exclusive uterine cavity integrity assessment system, safety are higher;
(5) it is not necessarily to swollen palace;
(6) post-operative recovery is fast, can restore normal life within 1 day.
Therefore, RF impedance endometrial ablation procedure both can achieve patient with breast cancer and carry out long-term endocrine agents The pretreated requirement in uterus when treatment, and operation safety, effectively, remain uterus, a system caused by avoiding because of uterectomy Column complication and adverse side effect.
We have discovered that estrogen receptor positive, progesterone receptor breast cancer patients with positive carry out under RF impedance control After Thermal balloon endometrial ablation, compared with the patient for not carrying out Thermal balloon endometrial ablation under RF impedance controls, in endocrine agents After treatment 24 months, on tumor suppressor gene VHL, synapse nucleoprotein, vascular endothelial growth factor and its expression of receptor, two groups of trouble The endometrium and basal layer tissue of person has apparent difference, presses down by the patient that RF impedance controls lower Thermal balloon endometrial ablation Oncogene VHL expression, which is apparently higher than, does not carry out endometrium processor, controls lower Thermal balloon endometrial ablation by RF impedance The expression of patient's synapse nucleoprotein controls lower endometrium removal significantly lower than endometrium processor is not carried out, by RF impedance The content expression of the vascular endothelial Porcine HGF and its receptor of art, which is significantly lower than, does not carry out endometrium processor.
Therefore, RF impedance control carries out endometrium removal, can be very good the generation of prevention carcinoma of endometrium, for Postoperative estrogen receptor positive, the progesterone receptor breast cancer patients with positive that need to carry out endocrine therapy for a long time plays well The effect for preventing endometrium carcinogenesis.
For those skilled in the art, technical solution documented by foregoing embodiments can still be repaired Change or equivalent replacement of some of the technical features, it is all within the spirits and principles of the present invention, made any to repair Change, equivalent replacement, improvement etc., should all be included in the protection scope of the present invention.

Claims (1)

1. RF impedance prevents carcinoma of endometrium caused by Mammary cancer endocrinotherapy, which is characterized in that
Using RF energy by endometrium gasify successive elimination inner membrance;
Impedance measurement: the impedance value between measuring electrode and tissue, when impedance is increased to 50 Ω, transmitting signal to RF energy emits Device, RF energy transmitter stop issuing RF energy, complete to eliminate.
CN201811115148.4A 2018-09-25 2018-09-25 RF impedance prevents carcinoma of endometrium caused by Mammary cancer endocrinotherapy Pending CN109363764A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811115148.4A CN109363764A (en) 2018-09-25 2018-09-25 RF impedance prevents carcinoma of endometrium caused by Mammary cancer endocrinotherapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811115148.4A CN109363764A (en) 2018-09-25 2018-09-25 RF impedance prevents carcinoma of endometrium caused by Mammary cancer endocrinotherapy

Publications (1)

Publication Number Publication Date
CN109363764A true CN109363764A (en) 2019-02-22

Family

ID=65401692

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201811115148.4A Pending CN109363764A (en) 2018-09-25 2018-09-25 RF impedance prevents carcinoma of endometrium caused by Mammary cancer endocrinotherapy

Country Status (1)

Country Link
CN (1) CN109363764A (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0693955B1 (en) * 1993-04-14 2003-01-02 Sherwood Services AG Apparatus for endometrial ablation
CN1437494A (en) * 2000-06-20 2003-08-20 效思因公司 System and method for heating the prostate gland using microwaves for treating and preventing the growth and spread of prostate tumor
CN101902978A (en) * 2007-03-13 2010-12-01 海尔特医疗公司 Apparatus and method for moderating return electrode temperature

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0693955B1 (en) * 1993-04-14 2003-01-02 Sherwood Services AG Apparatus for endometrial ablation
CN1437494A (en) * 2000-06-20 2003-08-20 效思因公司 System and method for heating the prostate gland using microwaves for treating and preventing the growth and spread of prostate tumor
CN101902978A (en) * 2007-03-13 2010-12-01 海尔特医疗公司 Apparatus and method for moderating return electrode temperature

Similar Documents

Publication Publication Date Title
AU2021290338B2 (en) Vapor ablation systems and methods
US10874455B2 (en) Ovarian neuromodulation and associated systems and methods
CN103271765B (en) Wear the neural ablation catheter of wall, Apparatus for () and method therefor through chamber
JP2020199286A (en) Vapor ablation systems and methods
US10737123B2 (en) Neuromodulation and associated systems and methods for the management of pain
CN201356648Y (en) Saline perfusion RF ablation catheter
CN110575251B (en) Balloon-type flexible microwave ablation catheter and ablation system and method adopting same
CN103027750B (en) Electrical ablation balloon radiofrequency catheter in percutaneous renal artery
CN107811703A (en) Treat intractable hypertension radiofrequency ablation of renal artery sympathetic nerve devices and methods therefor
CN203524766U (en) Trans-luminal wall-penetration nerve ablation catheter and equipment thereof
CN112353487A (en) Medical combined ablation needle capable of monitoring pressure and ablation method
US9839478B2 (en) Method for treating lower extremity varicose vein combined ultrasonic wave and microwave
CN204169925U (en) A kind of electrophysiologicalcatheter catheter
CN213940934U (en) Medical combined ablation needle for pressure monitoring
CN109363764A (en) RF impedance prevents carcinoma of endometrium caused by Mammary cancer endocrinotherapy
Sharp et al. Successful microwave ablation of endometrial carcinoma
Xia et al. Operative Hysteroscopy
US11076911B2 (en) Application of radiofrequency catheter ablation system to treatment of essential hypertension
Berlien Laser therapy of vascular malformations
CN217723643U (en) Medical Tunneler
Friedrich Jr Cryosurgery for urethral prolapse
CN202263053U (en) Aneurysm intervention type thermal therapy device
Sambrook et al. Second-generation treatment: microwave
Cockett et al. Transurethral Prostatic Resection
Cohen et al. 7.7 Hysteroscopic endometrial ablation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20190222

RJ01 Rejection of invention patent application after publication